SERPINE1 and polycystic ovary syndrome: Another RCT involving overweight and/or insulin-resistant women with polycystic ovary syndrome who received liraglutide or placebo found no effect on endogenous thrombin potential, though there was a trend toward decreased plasminogen activator inhibitor-1.137These studies might provide valuable insights into the potential mechanisms and effects of these novel medications on VTE.